Sunitinib Malate 100%

Sunitinib malate is a new oral multi-target anti-tumor drug, belongs to the multi-target tyrosine kinase inhibitor, the product name suntent, is developed by the United States Pfizer (Pfizer), has a dual anti-tumor effect, is the only breakthrough in the 2-year survival of advanced kidney cancer treatment drugs. It has a core position in the treatment of renal cell carcinoma and gastrointestinal stromal tumor, and was launched in the United States in February 2006, which is the first anti-cancer drug approved by the United States FDA to treat two diseases at the same time. Sunitinib Chemicalbook works by preventing tumor cells from getting the blood and nutrients they need to grow. Clinical trials have shown that the drug can slow the growth rate of gastrointestinal stromal tumors and reduce the size of kidney cell tumors. Sunitinib malate is the first novel targeted drug that can selectively target multiple tyrosine kinase receptors, combining two mechanisms of action: anti-angiogenesis, which interrupts blood supply to tumor cells, and anti-tumor, which directly attacks tumor cells. It represents the advent of a new wave of targeted therapies that can directly attack tumors without the toxic side effects of conventional chemotherapy.